Botulinum Toxin: An Innovative Approach to Treating Acne and Acne Scars
A systematic review
DOI:
https://doi.org/10.12775/JEHS.2025.79.57875Keywords
botulinum boxin, hidradenitis suppurativa, rosacea, acne scars managementAbstract
Introduction and Objective: Acne is one of the most common dermatological diseases. It mainly affects young people, but is more and more common in older people. There are reports on the effectiveness of treatment with botulinum toxin in acne vulgaris, acne rosacea and in the treatment of acne scars. The article takes into account research examining the effect of BTX as a method of treating acne. The results indicate that the use of BTX therapy as the method of treating acne may be effective. However, further research on its use in this therapy is necessary.
Methods: The article is a review on the effect of botulinum toxin on acne vulgaris, rosacea and on the treatment of scars. works from 1999-2024 were used to create the article. On their basis, conclusions were drawn.
Results: The results obtained based on the research review indicate a great potential for the use of botulinum toxin in the treatment of acne and acne scars. However, more research is needed on a larger population of patients to clearly assess the effectiveness of botulinum toxin therapy and adjust the appropriate doses of the preparation.
References
1. Li ZJ, Park SB, Sohn KC, et al. Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72(2):116-122. doi:10.1016/j.jdermsci.2013.06.00
2. Shirshakova M, Morozova E, Sokolova D, Pervykh S, Smirnova L. The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post-acne. Int J Dermatol. 2021;60(10):1232-1241. doi:10.1111/ijd.15574
3. Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol. 2008;7(9):847-850.
4.Birkett L, Dhar S, Singh P, Mosahebi A. Botulinum Toxin A in the Management of Acne Vulgaris: Evidence and Recommendations. Aesthet Surg J. 2022;42(7):NP507-NP509. doi:10.1093/asj/sjac037
5. Calvisi L, Diaspro A, Sito G. Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. J Cosmet Dermatol. 2022;21(9):3747-3753. doi:10.1111/jocd.14692
6. A New Treatment Regimen for Rosacea: OnabotulinumtoxinA - JDDonline - Journal of Drugs in Dermatology. JDDonline - Journal of Drugs in Dermatology. Dostęp 16.01.2025.
7.Shirshakova M, Morozova E, Sokolova D, Pervykh S, Smirnova L. Skuteczność toksyny botulinowej typu A (BTX-A) w leczeniu tłustego łojotoku skóry twarzy, rozszerzonych porów i zespołu objawów potrądzikowych. Int J Dermatol. 2021;60(10):1232-1241. doi: 10.1111/ijd.15574
8. Calvisi L, Diaspro A, Sito G. Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. J Cosmet Dermatol. 2022;21(9):3747-3753. doi:10.1111/jocd.14692
9. Grimstad Ø, Kvammen BØ, Swartling C. Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. American Journal of Clinical Dermatology. 2020;21:741–748. doi:10.1007/s40257-020-00537-9
10. Geoghegan L, Rodrigues R, Harrison CJ, Rodrigues JN. The Use of Botulinum Toxin in the Management of Hidradenitis Suppurativa: A Systematic Review. Plast Reconstr Surg Glob Open. 2022;10(11):e4660. Published 2022 Nov 18. doi:10.1097/GOX.0000000000004660
11. Qu H, Gao L. Botulinum toxin type A for the management of hidradenitis suppurativa. Am J Transl Res. 2021;13(12):14115-14120. Published 2021 Dec 15.
12. Campanati A, Martina E, Giuliodori K, Bobyr I, Consales V, Offidani A. Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage. Dermatol Ther. 2019;32(3):e12841. doi:10.1111/dth.12841
13. Ravi M, Trinidad J. Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review. J Drugs Dermatol. 2022;21(4):408-412. doi:10.36849/JDD.5747
14. Uhlenhake E, Yentzer BA, Feldman SR. Acne vulgaris and depression: a retrospective examination. J Cosmet Dermatol. 2010;9(1):59-63. doi:10.1111/j.1473-2165.2010.00478.x
15. Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP. Acne vulgaris: pathogenesis, treatment, and needs assessment. Dermatol Clin. 2012;30(1):99-ix. doi:10.1016/j.det.2011.09.001
16. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999;140(4):672-676. doi:10.1046/j.1365-2133.1999.02768.x
17. Birkett L, Dhar S, Singh P, Mosahebi A. Botulinum Toxin A in the Management of Acne Vulgaris: Evidence and Recommendations. Aesthet Surg J. 2022;42(7):NP507-NP509. doi:10.1093/asj/sjac037
18. Rahman E, Rao P, Philipp-Dormston W, et al. Intradermal Botulinum Toxin A on Skin Quality and Facial Rejuvenation: A Systematic Review and Meta-analysis. Plast Reconstr Surg Glob Open. 2024;12(8):e6084. Published 2024 Aug 23. doi:10.1097/GOX.0000000000006084
19. Fabi SG, Park JY, Goldie K, Wu W. Microtoxin for Improving Pore Size, Skin Laxity, Sebum Control, and Scars: A Roundtable on Integrating Intradermal Botulinum Toxin Type A Microdoses Into Clinical Practice. Aesthet Surg J. 2023;43(9):1015-1024. doi:10.1093/asj/sjad044
20. Kurzen H, Wessler I, Kirkpatrick C, Kawashima K, Grando S. The Non-neuronal Cholinergic System of Human Skin. Horm Metab Res. 2007;39(2):125-135. doi:10.1055/s-2007-961816
21. Rose AE, Goldberg DJ. Safety and Efficacy of Intradermal Injection of Botulinum Toxin for the Treatment of Oily Skin. Dermatologic Surgery. 2013;39(3):443-448. doi:10.1111/dsu.12097
22. Rose AE, Goldberg DJ. Safety and Efficacy of Intradermal Injection of Botulinum Toxin for the Treatment of Oily Skin. Dermatologic Surgery. 2013;39(3):443-448. doi:10.1111/dsu.12097
23. Ebrahim H, Elardi A, Khater S, Morsi H. Successful Topical Application of Botulinum Toxin After Microneedling Versus Microneedling Alone for the Treatment of Atrophic Post Acne Scars: A Prospective, Split-face, Controlled Study. J Clin Aesthet Dermatol. 2022;15(7):26-31.
24. Wang W, Liu G, Li X. The Efficacy and Safety of Botulinum Toxin Type A Injections in Improving Facial Scars: A Systematic Review and Meta-Analysis. Pharmacology. 2022;107(5-6):241-249. doi:10.1159/000522396
25. Guo X, Song G, Zhang D, Jin X. Efficacy of Botulinum Toxin Type A in Improving Scar Quality and Wound Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aesthet Surg J. 2020;40(5):NP273-NP285. doi:10.1093/asj/sjz165
26. Fabi SG, Park JY, Goldie K, Wu W. Microtoxin for Improving Pore Size, Skin Laxity, Sebum Control, and Scars: A Roundtable on Integrating Intradermal Botulinum Toxin Type A Microdoses Into Clinical Practice. Aesthet Surg J. 2023;43(9):1015-1024. doi:10.1093/asj/sjad044
27. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431-438. doi:10.1111/bjd.15122
28. Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea Treatment: Review and Update. Dermatol Ther (Heidelb). 2021;11(1):13-24. doi:10.1007/s13555-020-00461-0
29. van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol. 2021;22(4):457-465. doi:10.1007/s40257-021-00595-7
30. Maden S: Rosacea: an overview of its etiological factors, pathogenesis, classification and therapy options. Dermato. 2023, 3:241-62. 10.3390/dermato3040019
31. Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea Treatment: Review and Update. Dermatol Ther (Heidelb). 2021;11(1):13-24. doi:10.1007/s13555-020-00461-0
32. Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58-64. doi:10.1016/j.jdermsci.2018.12.004
33. Kim MJ, Kim JH, Cheon HI, et al. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema. Dermatol Surg. 2019;45(9):1155-1162. doi:10.1097/DSS.0000000000001819
34. Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41 Suppl 1:S9-S16. doi:10.1097/DSS.0000000000000277
35. Eshghi G, Khezrian L, Alirezaei P. Botulinum Toxin A in Treatment of Facial Flushing. Acta Med Iran. 2016;54(7):454-457.
36. Silva LC, Ferreira IL, Silveira ML, Steiner D: Prospective study for the treatment of rosacea flushing with botulinum toxin type A. Surg Cosmet Dermatol Rio de Janeiro. 2018, 10:121-6. 10.5935/scd1984-8773.20181021131
37. Yang R, Liu C, Liu W, Luo J, Cheng S, Mu X. Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea [published correction appears in Dermatol Ther (Heidelb). 2022 Oct;12(10):2295. doi: 10.1007/s13555-022-00798-8]. Dermatol Ther (Heidelb). 2022;12(10):2285-2294. doi:10.1007/s13555-022-00784-0
38. Tong Y, Luo W, Gao Y, Liu L, Tang Q, Wa Q. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea. Dermatol Ther. 2022;35(5):e15395. doi:10.1111/dth.15395
39. Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58-64. doi:10.1016/j.jdermsci.2018.12.004
40. Park KY, Kwon HJ, Kim JM, et al. A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea. Ann Dermatol. 2018;30(6):688-693. doi:10.5021/ad.2018.30.6.688
41. Calvisi L, Diaspro A, Sito G. Microbotox: A prospective evaluation of dermatological improvement in patients with mild-to-moderate acne and erythematotelangiectatic rosacea. J Cosmet Dermatol. 2022;21(9):3747-3753. doi:10.1111/jocd.14692
42. Luque A, Rojas AP, Ortiz-Florez A, Perez-Bernal J. Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea. J Clin Aesthet Dermatol. 2021;14(3):42-45.
43. Babadjouni A, Phong CH, Raffi J, Mesinkovska NA: Turning down the fire: the role of botulinum toxin microdroplets in refractory rosacea erythema. SKIN: J Cutan Med. 2022, 6:437-40. 10.25251/skin.6.5.16
44. Vasconcellos JB, Santos IO, Antelo DA: Use of botulinum toxin for rosacea: a pilot study [Uso da toxina botulínica para rosácea: estudo-piloto]. Surg Cosmet Dermatol. 2021, 13:20210019. 10.5935/scd1984-8773.2021130019
45. Gaón NQ, Herane MI, Diaz MY, Morales MW: Botulinum toxin for the treatment of erythema and flushing of rosacea with two different techniques: intradermal injections and facial electroporation. Surg Cosmet Dermatol Rio de Janeiro. 2020, 12:326-31. 10.5935/scd1984-8773.20201243747
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anna Podraza, Karolina Sacher, Oliwia Maciaszek, Mariola Turemka, Marianna Chmiel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 31
Number of citations: 0
